<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Increased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS)

dc.contributor.authorOzkan, Selcuk
dc.contributor.authorYilmaz, Omer Caglar
dc.contributor.authorYavuz, Bunyamin
dc.date.accessioned2026-10-09T21:49:11Z
dc.date.issued2020
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractObjective Polycystic ovary syndrome (PCOS) is a common disorder with important clinical consequences. Many studies have proven that hypertension is one of the most important comorbid disorders in PCOS. Masked hypertension is de?ned as a presence of normal of?ce blood pressure together with abnormal results in 24-h ambulatory blood pressure monitoring (ABPM). The prevalence of this condition in patients with PCOS is not well de?ned. The aim of this study was to evaluate the prevalence of masked hypertension in PCOS compared to control subjects. Methods Sixty patients with PCOS and 60 control subjects were enrolled in the study. All patients with PCOS and controls without a history of hypertension underwent physical examination including of?ce blood pressure measurement, ABPM, and measurement of laboratory and anthropometric parameters. Results Mean age was 30.5 +/- 6.6 in control group and 26.4 +/- 7.1 year in patients with PCOS (p= .001). Twenty-four patients (40%) had masked hypertension in PCOS group whereas 11 patients (18.3%) in the control group (p= .009). Twenty-four-hour diastolic blood pressure (p= .03), daytime systolic (p< .001), and daytime diastolic blood pressure (p= .01) and nighttime systolic blood pressure (p= .01) were signi?cantly higher in patients with PCOS compared with control group. Conclusions This study demonstrates increased masked hypertension prevalence in patients with PCOS. We suggest that all patients with PCOS should undergo ambulatory blood pressure monitoring for detecting masked hypertension.
dc.identifier.doi10.1080/10641963.2020.1772815
dc.identifier.endpage684
dc.identifier.issn1064-1963
dc.identifier.issn1525-6006
dc.identifier.issue8
dc.identifier.orcid0000-0001-5245-5216
dc.identifier.pmid32476487
dc.identifier.scopus2-s2.0-85086582364
dc.identifier.scopusqualityQ2
dc.identifier.startpage681
dc.identifier.urihttps://doi.org/10.1080/10641963.2020.1772815
dc.identifier.urihttps://hdl.handle.net/20.500.12794/3634
dc.identifier.volume42
dc.identifier.wosWOS:000542455000001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.digerScience Citation Index Expanded (SCI-EXPANDED)
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofClinical and Experimental Hypertension
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.relation.sdgGoal-05: Gender Equality
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260922
dc.subjectPolycystic Ovary Syndrome (Pcos)
dc.subjectHypertension
dc.subjectMasked Hypertension
dc.titleIncreased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS)
dc.typeArticle

Files